Abstract Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-analysis included all seven randomiz...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!